Hims & Hers Health Inc HIMS shares are rising on Wednesday after BofA Securities and Canaccord Genuity raised their respective price targets on the stock. Hims & Hers Health stock is charging ahead ...

Retail dip-buying remains strong in HIMS, with 59% of 1,100 Stocktwits poll voters saying they were buying the decline. ・The panel votes are recommendations, not FDA approvals, and the agency still ...

Wed, May 13, 2026 at 3:15 PM UTC Hims & Hers Health (NYSE:HIMS) absorbed another analyst downgrade. Bank of America cut its price objective on Hims & Hers stock to $30 from $32, while keeping a ...

BofA raised its HIMS price target to $37 from $36 but kept a 'Neutral' rating, warning that retention among oral Wegovy users may be "softer than some expect." Hims saw strong ini ...

Hims & Hers Health is in focus Friday after an FDA advisory panel on Thursday recommended adding four peptides to a federal ...

Shares of Hims & Hers Health (NYSE:HIMS) are under pressure after JPMorgan trimmed its price target on the consumer telehealth name following a messy first quarter. The firm lowered its price target ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

Learn more An FDA advisory panel backed compounding access for BPC-157, KPV, TB-500 and MOTS-C. The recommendation is not FDA ...

The average one-year price target for Hims & Hers Health (NYSE:HIMS) has been revised to $30.00 / share. This is a decrease of 30.94% from the prior estimate of $43.45 dated February 1, 2026. The ...

Last Thursday, Hims & Hers Health announced an expansion of its weight loss specialty by enabling providers to prescribe a Compounded Semaglutide Pill with the same active ingredient as Novo Nordisk’s ...